Maximus Enclomiphene Protocol review: is it worth it?

What is the Maximus Enclomiphene Protocol and how does it work?

Maximus (Maximus Tribe) is a men's-health telehealth company that sells several testosterone "protocols." The Enclomiphene Protocol — sometimes labeled "EP" or "Enclomiphene-Only" — is its oral, fertility-preserving option. Instead of giving you testosterone from the outside (gels, creams, or injections), it gives you enclomiphene citrate, a drug that prompts your own testes to make more testosterone.

The process is fully remote and runs roughly like this:

1. You complete an online medical intake questionnaire.
2. You take an at-home blood test (Maximus uses a Tasso+ upper-arm device) to measure baseline total testosterone and related hormones; results typically return in about 48 hours.
3. A licensed clinician reviews your labs and history asynchronously and, if appropriate, writes a prescription. Notably, in most cases there is no live video visit before treatment begins — the evaluation and prescription decision happen by message.
4. Compounded enclomiphene capsules ship to your door, and you can message the medical team for follow-up.

This convenience is the core appeal, and it is also the core trade-off: enrollment is fast and low-friction, but the human-clinician touchpoints are thinner than at clinics that require a video consult.

How does enclomiphene actually raise testosterone?

Enclomiphene is the trans-isomer (zuclomiphene is the cis-isomer) of clomiphene citrate (the fertility drug Clomid) and belongs to a class called selective estrogen receptor modulators (SERMs). It works at the brain, not the testes.

Normally, estrogen in the bloodstream signals the hypothalamus and pituitary to slow down — a negative-feedback loop. Enclomiphene blocks estrogen receptors at the hypothalamus, so the brain "thinks" estrogen is low and ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH tells the testes to produce more testosterone; FSH supports sperm production. The result: higher testosterone driven by your own physiology (NIH/NCBI).

This mechanism is the crucial distinction from standard TRT. External testosterone shuts down LH and FSH through the same feedback loop, which shrinks the testes and suppresses sperm — a major reason men who want to preserve fertility avoid conventional TRT. Because enclomiphene stimulates rather than replaces, it tends to maintain or improve sperm parameters while raising testosterone, which is its single biggest theoretical advantage (PMID 25044085).

Is enclomiphene FDA-approved?

No — and this deserves a clear, honest answer because the marketing around it can be slippery. Enclomiphene was developed by Repros Therapeutics under the brand name Androxal for secondary hypogonadism. In December 2015 the FDA issued a Complete Response Letter declining approval, saying that based on recent scientific developments the design of the Phase 3 program was no longer adequate to demonstrate clinical benefit and recommending an additional Phase 3 study (Repros Therapeutics press release / SEC filing, December 2015). Those further trials were not completed, and development was effectively shelved. There is no FDA-approved finished enclomiphene drug product on the U.S. market.

What Maximus dispenses is therefore compounded enclomiphene, prepared by a 503A compounding pharmacy on a patient-specific basis with a valid prescription. This is legal off-label/compounded use, but it carries real caveats: in June 2022, the FDA's Pharmacy Compounding Advisory Committee voted against adding enclomiphene to the 503A bulk-substances list (FDA, PCAC June 2022). Compounded products are not FDA-reviewed for safety, efficacy, or manufacturing quality the way approved drugs are, and potency or purity can vary between pharmacies. If you've seen enclomiphene marketed as a "supplement," that is incorrect — it is a drug, not a dietary supplement (DoD Operation Supplement Safety).

How well does it work? What the evidence shows

The clinical evidence for enclomiphene is genuinely encouraging but not extensive, and it is built largely on short, mid-sized trials rather than the large, long-duration outcome studies that underpin many approved drugs.

The most-cited trial is a randomized Phase II study published in *Fertility and Sterility* (2014) comparing enclomiphene citrate to topical testosterone gel in men with secondary hypogonadism. Enclomiphene raised morning serum testosterone into a range comparable to the gel, while increasing LH and FSH and preserving sperm counts — the gel did the opposite, suppressing those markers (PMID 25044085).

A 2025 systematic review and meta-analysis of 10 randomized controlled trials (819 patients, 374 on SERM therapy) found that SERM therapy — clomiphene/enclomiphene — significantly raised hormone levels versus placebo (PMID 41066380):

• Total testosterone: mean difference of roughly +274 ng/dL (95% CI ~192–356)
• LH: mean difference ~+4.7 IU/L
• FSH: mean difference ~+4.6 IU/L

Critically, the meta-analysis found no significant difference in testosterone levels between SERM therapy and testosterone gel, while SERMs produced significantly higher LH and FSH. The authors concluded SERM therapy is an effective alternative to gel for raising testosterone in functional hypogonadism.

Three honest limitations temper this:

• The trials were generally short (weeks to a few months), so we have limited data on long-term efficacy and durability.
• The meta-analysis explicitly noted it was underpowered for safety endpoints and showed high heterogeneity in some outcomes.
• Most importantly, the studies measured hormone levels and sperm counts, not hard clinical endpoints. There is no large trial proving enclomiphene reduces cardiovascular events, fractures, or mortality. A higher number on a lab report is not the same as a proven long-term health benefit, and that gap applies to most testosterone therapies, not just enclomiphene.

Who is the Enclomiphene Protocol best for — and who should skip it?

Best candidates:

• Men with lab-confirmed low testosterone driven by secondary hypogonadism (low T with low or "inappropriately normal" LH), where the problem is upstream signaling rather than failed testes.
• Men who want to preserve fertility or keep the option open — this is enclomiphene's standout use case and where it most clearly beats conventional TRT.
• Men who prefer an oral pill over injections, gels, or pellets.
• Younger men who want to avoid testicular atrophy and the dependency that can come with exogenous testosterone.

Who should be cautious or skip it:

• Men with primary hypogonadism (testicular failure / already-high LH and FSH). If the testes can't respond, stimulating them harder won't help, and TRT is the appropriate path.
• Anyone uncomfortable taking a non-FDA-approved, compounded medication off-label.
• Men with a personal or strong family history of venous thromboembolism (blood clots), certain liver disease, or hormone-sensitive conditions — SERMs as a class can raise clot risk and warrant in-person evaluation.
• Men who want a thorough, examination-based work-up. The asynchronous, message-based model is convenient but is not a substitute for a clinician who physically examines you and rules out secondary causes (pituitary tumor, sleep apnea, medication effects, etc.).

A symptom of low testosterone plus one low reading is not a diagnosis. Guidelines from professional societies recommend confirming low testosterone with at least two morning measurements and investigating the underlying cause before treating.

Side effects and safety

Enclomiphene is generally well tolerated in the published trials, and its side-effect profile appears milder than its cousin clomiphene. That difference is thought to be largely mechanistic: clomiphene contains zuclomiphene, a long-half-life isomer (reported around 5–7 days, with traces detectable in plasma for weeks after dosing) that accumulates with chronic use and is implicated in many of clomiphene's visual disturbances; purified enclomiphene has a much shorter half-life (reported on the order of several to ~10 hours) and lacks zuclomiphene, which is a leading explanation for its lower rate of vision-related complaints.

Reported and plausible side effects include:

• Headache, nausea, and hot flashes — the most commonly reported, usually mild and often fading after the first couple of weeks.
• Mood changes — most men report improved mood as testosterone rises, but some describe transient irritability early on.
• Visual disturbances (blurred vision, light sensitivity, "trails") — uncommon with enclomiphene but a recognized SERM class effect; any visual change is a reason to stop and contact a clinician.
• Rising estradiol, since more testosterone means more aromatization; some protocols monitor this.

The most serious class-level concern is venous thromboembolism (blood clots), recognized with SERMs generally. Because the compounded product is not FDA-reviewed, the precise risk in healthy hypogonadal men is not well quantified — another reason the thin long-term safety data matters. Anyone on the protocol should have periodic lab monitoring (testosterone, estradiol, LH/FSH, and a hematocrit/CBC) rather than treating set-and-forget.

How much does it cost and what's the value?

Maximus prices the Enclomiphene Protocol on a commitment-tiered model. Based on the company's published pricing, the medication subscription runs approximately:

• ~$99.99/month on an annual commitment (the heavily advertised "starting at" price)
• ~$149.99/month on a quarterly plan
• ~$199.99/month month-to-month

At-home lab testing is billed separately (around $99.99 per test), and ongoing monitoring requires repeat testing. Clinician oversight is bundled into the subscription. Maximus also advertises a testosterone guarantee — a refund of up to three months of medication cost if your total testosterone doesn't rise by at least a stated threshold (the company has marketed a 10% increase) — though terms and conditions apply and should be read carefully.

On value: the recurring cost is meaningfully higher than buying generic compounded enclomiphene through a local prescriber, and lower than many full-service TRT clinics with injections plus ancillary drugs. The premium you pay Maximus is for convenience, packaging, and brand — not for a unique formulation. Prices change frequently; verify current numbers directly before enrolling.

How does it compare to alternatives?

• vs. Testosterone gels/injections (true TRT): Comparable testosterone elevation per the meta-analysis, but TRT suppresses fertility and can shrink the testes; enclomiphene preserves both. TRT (testosterone itself) has decades more data and FDA-approved products; enclomiphene does not.
• vs. Clomiphene (Clomid, off-label): Clomiphene is cheaper and more widely prescribed off-label for the same goal, but carries a higher reported rate of mood and visual side effects due to the zuclomiphene isomer. Enclomiphene is the "cleaner" SERM in theory, at higher cost.
• vs. hCG (human chorionic gonadotropin): hCG also stimulates endogenous testosterone and preserves fertility, but requires injections and is a separate supply and access story.
• vs. other telehealth platforms (e.g., Hims, PeterMD, Hone): Several competitors now offer compounded enclomiphene at similar price points. Maximus differentiates on brand, the testosterone guarantee, and a polished app — but its largely asynchronous (no required video visit) model is a point against it relative to platforms that mandate a clinician consult, and at least one independent reviewer flagged its automated chatbot for giving inaccurate information.

The bottom line

The Maximus Enclomiphene Protocol is a real, physician-supervised way to access a legitimate, evidence-supported molecule, and for the right man — confirmed secondary hypogonadism who wants to preserve fertility and prefers a pill — it is a reasonable, science-backed choice. The clinical data show enclomiphene reliably raises testosterone, LH, and FSH and matches testosterone gel for raising T while protecting sperm production.

But buyers should go in clear-eyed on three points: enclomiphene is not FDA-approved and is dispensed as a compounded, off-label drug (with the variability that implies); the evidence base is short-term and lacks hard clinical-outcome data; and the convenience-first, often video-free intake model trades clinical thoroughness for speed. This is a service best used by men who have a confirmed diagnosis, understand the regulatory caveats, and commit to ongoing lab monitoring — not as a shortcut to "boost T" without a proper work-up. If you fit that profile, it can be a sensible option; if you don't, an in-person evaluation should come first.